Zsofia Kote-Jarai

Summary

Affiliation: Institute of Cancer Research
Country: UK

Publications

  1. ncbi BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients
    Z Kote-Jarai
    Oncogenetics team, The Institute of Cancer Research, Sutton SM2 5NG, UK
    Br J Cancer 105:1230-4. 2011
  2. ncbi A recurrent truncating germline mutation in the BRIP1/FANCJ gene and susceptibility to prostate cancer
    Z Kote-Jarai
    Translational Cancer Genetics Team, The Institute of Cancer Research, Sutton, Surrey, UK
    Br J Cancer 100:426-30. 2009
  3. ncbi Mutation analysis of the MSMB gene in familial prostate cancer
    Z Kote-Jarai
    Translational Cancer Genetics Team, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
    Br J Cancer 102:414-8. 2010
  4. ncbi Identification of a novel prostate cancer susceptibility variant in the KLK3 gene transcript
    Z Kote-Jarai
    The Institute of Cancer Research, Sutton, Surrey SM2 5NG, UK
    Hum Genet 129:687-94. 2011
  5. ncbi Accurate prediction of BRCA1 and BRCA2 heterozygous genotype using expression profiling after induced DNA damage
    Zsofia Kote-Jarai
    Translational Cancer Genetics Team, The Institute of Cancer Research, Sutton, Surrey, United Kingdom
    Clin Cancer Res 12:3896-901. 2006
  6. ncbi BRCA1/BRCA2 mutation status and analysis of cancer family history in participants of the Royal Marsden Hospital tamoxifen chemoprevention trial
    Zsofia Kote-Jarai
    Translational Cancer Genetics Team, Section of Cancer Genetics, The Institute of Cancer Research, Sutton, Surrey SM2 5NG, UK
    Cancer Lett 247:259-65. 2007
  7. ncbi Gene expression profiling after radiation-induced DNA damage is strongly predictive of BRCA1 mutation carrier status
    Zsofia Kote-Jarai
    Translational Cancer Genetics, The Institute of Cancer Research, Sutton, Surrey, UK
    Clin Cancer Res 10:958-63. 2004
  8. ncbi Multiple newly identified loci associated with prostate cancer susceptibility
    Rosalind A Eeles
    The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK
    Nat Genet 40:316-21. 2008
  9. ncbi Loss of heterozygosity at the BRCA1 and BRCA2 loci detected in ductal lavage fluid from BRCA gene mutation carriers and controls
    Imogen Locke
    The Institute of Cancer Research, London, UK
    Cancer Epidemiol Biomarkers Prev 15:1399-402. 2006
  10. ncbi Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene
    Stephen M Edwards
    Translational Cancer Genetics Team, Institute of Cancer Research, Sutton, Surrey, United Kingdom
    Am J Hum Genet 72:1-12. 2003

Detail Information

Publications22

  1. ncbi BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients
    Z Kote-Jarai
    Oncogenetics team, The Institute of Cancer Research, Sutton SM2 5NG, UK
    Br J Cancer 105:1230-4. 2011
    ..We previously estimated that about 2% of PrCa cases diagnosed ≤ 55 years harbour a BRCA2 mutation and PrCa among BRCA2 carriers has been shown to be more aggressive, with poorer survival...
  2. ncbi A recurrent truncating germline mutation in the BRIP1/FANCJ gene and susceptibility to prostate cancer
    Z Kote-Jarai
    Translational Cancer Genetics Team, The Institute of Cancer Research, Sutton, Surrey, UK
    Br J Cancer 100:426-30. 2009
    ....
  3. ncbi Mutation analysis of the MSMB gene in familial prostate cancer
    Z Kote-Jarai
    Translational Cancer Genetics Team, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
    Br J Cancer 102:414-8. 2010
    ..The MSMB protein is underexpressed in PrCa and it was previously proposed to be an independent marker for the recurrence of cancer after radical prostatectomy...
  4. ncbi Identification of a novel prostate cancer susceptibility variant in the KLK3 gene transcript
    Z Kote-Jarai
    The Institute of Cancer Research, Sutton, Surrey SM2 5NG, UK
    Hum Genet 129:687-94. 2011
    ..Using molecular dynamic simulation, we showed evidence that this variant has the potential to introduce alterations in the protein or affect RNA splicing. We propose that rs17632542 may directly influence PrCa risk...
  5. ncbi Accurate prediction of BRCA1 and BRCA2 heterozygous genotype using expression profiling after induced DNA damage
    Zsofia Kote-Jarai
    Translational Cancer Genetics Team, The Institute of Cancer Research, Sutton, Surrey, United Kingdom
    Clin Cancer Res 12:3896-901. 2006
    ..We aimed to establish if BRCA1/BRCA2 mutation carriers could be distinguished from noncarriers based on expression profiling of normal cells...
  6. ncbi BRCA1/BRCA2 mutation status and analysis of cancer family history in participants of the Royal Marsden Hospital tamoxifen chemoprevention trial
    Zsofia Kote-Jarai
    Translational Cancer Genetics Team, Section of Cancer Genetics, The Institute of Cancer Research, Sutton, Surrey SM2 5NG, UK
    Cancer Lett 247:259-65. 2007
    ..03) in the cancers developing in tamoxifen-treated patients. These results suggest that tamoxifen is less likely to be effective at reducing breast cancers which are ER negative and also in some individuals at higher HR...
  7. ncbi Gene expression profiling after radiation-induced DNA damage is strongly predictive of BRCA1 mutation carrier status
    Zsofia Kote-Jarai
    Translational Cancer Genetics, The Institute of Cancer Research, Sutton, Surrey, UK
    Clin Cancer Res 10:958-63. 2004
    ..The impact of the presence of a germ-line BRCA1 mutation on gene expression in normal breast fibroblasts after radiation-induced DNA damage has been investigated...
  8. ncbi Multiple newly identified loci associated with prostate cancer susceptibility
    Rosalind A Eeles
    The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK
    Nat Genet 40:316-21. 2008
    ..7 x 10(-29)). We confirmed previous reports of common loci associated with prostate cancer at 8q24 and 17q. Moreover, we found that three of the newly identified loci contain candidate susceptibility genes: MSMB, LMTK2 and KLK3...
  9. ncbi Loss of heterozygosity at the BRCA1 and BRCA2 loci detected in ductal lavage fluid from BRCA gene mutation carriers and controls
    Imogen Locke
    The Institute of Cancer Research, London, UK
    Cancer Epidemiol Biomarkers Prev 15:1399-402. 2006
    ..Further studies are required to evaluate the specificity and predictive value of LOH in ductal lavage fluid for breast cancer development...
  10. ncbi Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene
    Stephen M Edwards
    Translational Cancer Genetics Team, Institute of Cancer Research, Sutton, Surrey, United Kingdom
    Am J Hum Genet 72:1-12. 2003
    ..These results confirm that BRCA2 is a high-risk prostate-cancer-susceptibility gene and have potential implications for the management of early-onset prostate cancer, in both patients and their relatives...
  11. ncbi Detection of TMPRSS2-ERG translocations in human prostate cancer by expression profiling using GeneChip Human Exon 1.0 ST arrays
    Sameer Jhavar
    Institute of Cancer Research, Male Urological Cancer Research Centre, Sutton, Surrey SM2 5NG, UK
    J Mol Diagn 10:50-7. 2008
    ..These studies demonstrate that expression analyses using exon arrays represent a valuable approach for detecting ETS gene translocation in prostate cancer, in parallel with analyses of gene expression profiles...
  12. ncbi Overexpression of RAD51 occurs in aggressive prostatic cancer
    Anita Mitra
    Translational Cancer Genetics Team, Section of Cancer Genetics, The Institute of Cancer Research, Sutton, Surrey, UK
    Histopathology 55:696-704. 2009
    ..To test the hypothesis that, in a matched series of prostatic cancers, either with or without BRCA1 or BRCA2 mutations, RAD51 protein expression is enhanced in association with BRCA mutation genotypes...
  13. ncbi Gene promoter hypermethylation in ductal lavage fluid from healthy BRCA gene mutation carriers and mutation-negative controls
    Imogen Locke
    Translational Cancer Genetics Team, Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
    Breast Cancer Res 9:R20. 2007
    ....
  14. ncbi Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study
    Zsofia Kote-Jarai
    The Institute of Cancer Research, Sutton, Surrey, UK
    Nat Genet 43:785-91. 2011
    ..7 × 10(-24)). We also identified a SNP in TERT more strongly associated with PrCa than that previously reported. More than 40 PrCa susceptibility loci, explaining ∼25% of the familial risk in this disease, have now been identified...
  15. ncbi Identification of seven new prostate cancer susceptibility loci through a genome-wide association study
    Rosalind A Eeles
    The Institute of Cancer Research, Sutton, Surrey, UK
    Nat Genet 41:1116-21. 2009
    ..In addition to replicating previous associations, we identified seven new prostate cancer susceptibility loci on chromosomes 2, 4, 8, 11 and 22 (with P = 1.6 x 10(-8) to P = 2.7 x 10(-33))...
  16. ncbi Multiple novel prostate cancer predisposition loci confirmed by an international study: the PRACTICAL Consortium
    Zsofia Kote-Jarai
    Section of Cancer Genetics Team, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, United Kingdom
    Cancer Epidemiol Biomarkers Prev 17:2052-61. 2008
    ..This study provides strong confirmation of these susceptibility loci in multiple populations and shows that they make an important contribution to prostate cancer risk prediction...
  17. ncbi Identification of new genetic risk factors for prostate cancer
    Michelle Guy
    Section of Cancer Genetics, The Institute of Cancer Research, Sutton, Surrey, UK
    Asian J Androl 11:49-55. 2009
    ..Follow-up validation studies, as well as studies to explore the psychological implications of genetic profile testing, will be vital prior to roll out into healthcare...
  18. ncbi Relationship between glutathione S-transferase M1, T1, and P1 polymorphisms and chronic lymphocytic leukemia
    Martin Yuille
    Academic Department of Haematology and Cytogenetics, and the Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey, United Kingdom
    Blood 99:4216-8. 2002
    ..8-fold (OR = 2.8, 95% confidence interval: 1.1-6.9). Our findings suggest that heritable GST status may influence the risk of developing CLL...
  19. ncbi Integration of ERG gene mapping and gene-expression profiling identifies distinct categories of human prostate cancer
    Sameer Jhavar
    Institute of Cancer Research, Male Urological Cancer Research Centre, Sutton, Surrey, UK
    BJU Int 103:1256-69. 2009
    ....
  20. ncbi Lymphocyte radiosensitivity in BRCA1 and BRCA2 mutation carriers and implications for breast cancer susceptibility
    Julian Barwell
    Clinical Genetics, St George s University of London, United Kingdom
    Int J Cancer 121:1631-6. 2007
    ..Our results show a demonstrable impairment in irradiation induced DNA repair in women with heterozygous germline BRCA1 and BRCA2 mutations prior to being diagnosed with breast cancer...
  21. ncbi Polyglutamine repeat length in the AIB1 gene modifies breast cancer susceptibility in BRCA1 carriers
    Luna Kadouri
    Sharett Institute of Oncology, Hebrew University Hadassah Medical Center, Jerusalem, Israel
    Int J Cancer 108:399-403. 2004
    ..Longer repeat length correlates with elevated risk, whereas in carriers of a shorter AIB1 allele BC risk was reduced. The AIB1 polyglutamine length did not affect BC risk among BRCA2 mutation carriers...
  22. ncbi Multiple loci with different cancer specificities within the 8q24 gene desert
    Maya Ghoussaini
    Cancer Research UK Department of Oncology, University of Cambridge, Strangeways Research Laboratory, Worts Causeway, CB1 8RN, Cambridge, UK
    J Natl Cancer Inst 100:962-6. 2008
    ..We conclude that there are at least five separate functional variants in this region...